RENNOVA HEALTH, INC. (NASDAQ:RNVA) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
As previously disclosed in its Form 8-K filed on September 14,
2016, on September 13, 2016, Nasdaq granted Rennova Health, Inc.
(the Company) a 180-day extension, or until March 13, 2017, to
regain compliance with the minimum $1.00 per share requirement
for continued inclusion under Nasdaq Listing Rule 5550(a)(2) (the
Rule). On March 9, 2017, the Company received a letter from
Nasdaq notifying the Company that it has regained compliance with
the Rule. The letter noted that the closing bid price of the
Companys common stock has been in excess of the $1.00 minimum
requirement for the last 10 consecutive trading days from
February 23 to March 8, 2017. As a result, Nasdaq considers the
matter closed.
On March 10, 2017, the Company issued a press release that it has
regained compliance with the Rule. A copy of the press release is
attached as Exhibit 99.1 to this Current Report and is
incorporated by reference herein.
Item9.01. Financial Statements and Exhibits.
| (d)Exhibits. | ||
| Exhibit | ||
| Number | Description | |
| 99.1 | Press release dated March 10, 2017 | |
About RENNOVA HEALTH, INC. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc. RENNOVA HEALTH, INC. (NASDAQ:RNVA) Recent Trading Information
RENNOVA HEALTH, INC. (NASDAQ:RNVA) closed its last trading session down -0.04 at 2.37 with 2,470,474 shares trading hands.
